普恩复对缺血性脑卒中病人LPA及神经功能转归影响

目的观察普恩复对缺血性脑卒中病人血清溶血磷脂酸（LPA）含量及神经功能转归的影响。方法选择缺血性脑卒中病人78例,随机分为治疗组（38例）和对照组（40例）。治疗组在对照组治疗的基础上,加用普恩复口服治疗,每次60万单位,每天3次,连用20 d。分别于治疗前和治疗后取静脉血测定LPA水平,并于治疗后应用欧洲卒中量表（ESS）进行神经功能转归评价。结果对照组与治疗组治疗20 d后LPA水平均较治疗前显著降低（t=17.00、34.62,P〈0.01）,ESS评分亦显著改善（t=-5.57、-8.85,P〈0.05）;与对照组相比,治疗组上述指标改善更明显（t=-13.71、3.21,P〈0.01）。结论普恩复能降低血清LPA的含量,改善缺血性脑卒中病人的预后。

EFFECT OF PANFORD ON LYSOPHOSPHATIDIC ACID AND FUNCTIONAL RECOVERY IN PATIENTS WITH ISCHEMIC STROKE

Objective To investigate the effects of Panford on serum [ysophosphatidic acid （LPA） level and functional reeovery in patients with ischemic stroke （IS）. Methods Seventy eight IS patients were randomly assigned to Panford group （38） and control group （40）. Panford 600 000 U, t. i. d. for 20 days, were given to patients in Panford group in addition to routine therapy. LPA was measured before and after treatment, and the European stroke scale （ESS） used for evaluation. Results After therapy, the LPA levels in both groups decreased （t=17.00,34.62;P〈0.01）, and the ESS scores improved （t=-5.57,-8.85, P〈0.05）. More significant improvement of the above parameters was observed in Panford group compared with that of the control （t=-13.71,3.21 ;P〈0.01）. Conclusion Panford can decline serum LPA in IS, thus improve the prognosis of the disease.